Press release
Study Shows Promise for Semaglutide in Weight Management: Doctor Roya Institute Offers New Program
Doctor Roya Institute, led by Dr. Roya Jafari-Hassad, is pleased to announce a new weight loss program that utilizes Semaglutide, a medication scientifically proven to promote weight loss.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a type of medication that helps regulate blood sugar levels. It has also been shown to be effective in promoting weight loss by reducing appetite and cravings.
"We are excited to offer this new program to our patients who are struggling to lose weight," says Dr. Roya Jafari-Hassad, founder of Doctor Roya Institute. "Semaglutide, when combined with our personalized lifestyle coaching program, can help patients achieve significant and sustainable weight loss."
Doctor Roya Institute is a leading medical practice dedicated to helping patients achieve their weight loss goals. The institute is led by Dr. Roya Jafari-Hassad, a board-certified physician with extensive experience in weight loss management. Dr. Jafari-Hassad and her team offer a variety of weight loss programs, including medication-assisted programs like the Semaglutide program.
The Doctor Roya Institute weight loss program with Semaglutide includes:
* A consultation with Dr. Jafar-Hassan to discuss weight loss goals and develop a personalized treatment plan
* Weekly Semaglutide injections
* Personalized lifestyle coaching, including guidance on diet, exercise, and behavior modification
"I have been very impressed with the results that my patients have achieved with the Semaglutide weight loss program," says Dr. Jafari-Hassad. "In addition to weight loss, many patients have also reported improvements in their overall health, including better blood sugar control and increased energy levels."
"We are excited to offer this new program to our patients who are struggling to lose weight," she elaborates. "Semaglutide, when combined with our personalized lifestyle coaching program, can help patients achieve significant and sustainable weight loss."
"For years, I tried everything to lose weight, but nothing seemed to work," says S. M. Gellar, a patient at Doctor Roya Institute. "Since starting the Semaglutide program, I've finally been able to lose weight and keep it off. I feel so much better about myself, and I have more energy to do the things I love."
Here's what you need to know about Semaglutide:
* Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a type of medication that has been shown to be effective in promoting weight loss.
* It works by slowing gastric emptying, which increases feelings of fullness and suppresses hunger.
* In clinical trials, almost 90% of people lost at least 5% of their weight, and average weight loss was 10%-17%.
* Semaglutide is used in conjunction with lifestyle changes, such as a healthy diet and exercise, to help patients achieve and maintain weight loss.
A little about its side effects:
* Semaglutide is generally well-tolerated, but some common side effects include nausea, vomiting, constipation, diarrhea, abdominal pain, fatigue, headaches, and injection site reactions.
* It is important to note that not everyone is a candidate for semaglutide. Patients should consult with a doctor to see if this medication is right for them.
About Dr. Roya Jafari-Hassad
Dr. Roya Jafari-Hassad is a distinguished physician, educator, and speaker, renowned for her expertise in family medicine, skincare, women's health, functional and anti-aging medicine. As the Medical Director of Advanced Medical Health Services and Founder of Hope, Life, and Dream Centers, she leads with a commitment to providing the highest quality medical care with compassion and progressive technology. With accolades as a top family physician and board-certified anti-aging specialist, Doctor Roya is dedicated to transforming lives through personalized care and innovative treatments.
For more information about Dr. Roya Jafari-Hassad and her groundbreaking aesthetics treatments and solutions, please visit www.doctorroya.com [http://www.doctorroya.com/].
Media Contact
Company Name: The Empire Publishers
Contact Person: Andreea Stan
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=study-shows-promise-for-semaglutide-in-weight-management-doctor-roya-institute-offers-new-program]
Phone: (844) 636-4576
Address:12808 W Airport Blvd, 270M
City: Sugar Land
State: Texas 77478
Country: United States
Website: https://www.theempirepublishers.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Study Shows Promise for Semaglutide in Weight Management: Doctor Roya Institute Offers New Program here
News-ID: 3540027 • Views: …
More Releases from ABNewswire
The Best Online Agencies in Denmark - The List of Top 5 Is Out
The digital marketing landscape is full of agencies promising growth and success. But which ones actually deliver? We have reviewed some of Denmark's most talked-about digital marketing agencies and found the top 5. Leading the list is The Morning Show, a boutique agency that has proven its ability to take small and mid-sized e-commerce businesses to new heights.
1. The Morning Show - Flexibility and Proven Results
The Morning Show has built…
Renovation Reach Media Launches AI-Powered Lead Generation Solutions to Help Rem …
USA - September 10, 2025 - Renovation Reach Media [https://renovationreachmedia.com/], an emerging startup dedicated to transforming the remodeling industry, has officially announced the launch of its AI-powered solutions designed to help contractors and remodelers scale their businesses. By combining advanced artificial intelligence with strategic digital advertising, the company is focused on solving one of the industry's biggest challenges: generating consistent, high-quality leads that actually convert.
Remodelers and contractors often face wasted…
Homelessness Is Not One Problem - It's a Spectrum
Toms River, NJ - Homelessness is not a single problem with a single solution. It exists on a spectrum shaped by countless interwoven factors-and, like most complex social challenges, it resists quick fixes.
"At one end of that spectrum are the working poor, families living paycheck to paycheck and one unexpected crisis away from losing their homes," said Kimberly Veith, Chief Executive Officer of Bright Harbor Healthcare [https://brightharbor.org/]. "On the other…
SilverwindMC Launches Minecraft Server Adventure with Unique Generator-Based Sur …
A new world of adventure opens today for Minecraft players with the official launch of SilverwindMC, a server offering an innovative blend of generator-based gameplay and classic survival. Designed for both new and veteran players, SilverwindMC introduces a feature-rich environment packed with custom content aimed at creating the ultimate Minecraft experience.
SilverwindMC distinguishes itself with a unique core mechanic that combines the resource-gathering satisfaction of generator-based gameplay with the open-world danger…
More Releases for Semaglutide
Rising Diabetes Prevalence Drives Growth in Liraglutide and Semaglutide Markets …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Liraglutide And Semaglutide Industry Market Size Be by 2025?
In recent times, the liraglutide and semaglutide market has seen quick and impressive growth. The growth is projected to continue, with the market size increasing from $15.19 billion in 2024 to an estimated $16.98 billion in 2025,…
Higher max dose guidance for semaglutide offers hope
A new study increases max-dose guidance for semaglutide. This offers hope for those who didn't reach their weight goals. The Injection and Infusion Clinic of ABQ now provides higher-dose weight loss injections, backed by the STEP UP trial, which showed 20.7% average weight loss with higher-dose semaglutide. 33.2% of participants lost over 25% of their body weight. Ideal for those who plateaued, this science-backed treatment supports long-term weight management with…
Recent Developments in the Global Semaglutide Market
Global semaglutide market is anticipated to grow at a significant CAGR of 9.1% during the forecast period (2024-2031). The market growth is driven by the rise in the incidences of diabetes and obesity globally, as it supports controlling blood sugar levels and improving insulin sensitivity. The prolific rise in demand for novel therapies and innovative treatment options, owing to the increasing prevalence of TZDs is also contributing to the market…
Find Trusted Compounding Pharmacies Offering Semaglutide Near You
Compounded semaglutide has gained popularity as an effective treatment for weight loss and diabetes management. If you're looking for a personalized medication solution, finding a trusted compounding pharmacy near you is essential. These specialized pharmacies create customized versions of medications like semaglutide, tailored to your specific health needs.
To find a reliable compounding pharmacy, start by researching local pharmacies with certified pharmacists who specialize in compounding. Check reviews, ensure the pharmacy…
Huateng Pharma Proudly Unveils Its New Product - Semaglutide Side Chains
Huateng Pharma, a distinguished provider of premium pharmaceutical intermediates, proudly unveils its latest breakthrough: Semaglutide Side Chain. This groundbreaking addition to Huateng Pharma's esteemed portfolio signifies a remarkable leap forward in pharmaceutical innovation, showcasing a diverse array of compounds including AEEA-AEEA (CAS NO.: 1143516-05-5), SNAC (CAS NO.: 203787-91-1), tBuO-Ste-Glu(AEEA-AEEA)-OtBu (CAS NO.:1118767-16-0), and Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH (CAS NO.: 1662688-20-1).
Semaglutide Side Chain serves as a pivotal component in the synthesis of semaglutide, an innovative…
Huateng Pharma Develops Intermediates of Semaglutide For TD2
According to the latest IDF Diabetes map, the global prevalence of diabetes reached 10.5% in 2021, with 537 million adults living with diabetes. China has become a disaster zone for diabetes, with the largest number of adults with diabetes in the world. In the past 10 years (2011-2021), the number of people with diabetes in China increased from 90 million to 140 million, an increase of 56%. The total number…
